US 12,370,167 B2
Blood-brain barrier permeability regulator and use thereof
Fuqiang Hu, Hangzhou (CN); Lijuan Wen, Hangzhou (CN); Hong Yuan, Hangzhou (CN); Kai Wang, Hangzhou (CN); and Tingting Meng, Hangzhou (CN)
Assigned to ZHEJIANG UNIVERSITY, Hangzhou (CN)
Appl. No. 17/425,415
Filed by ZHEJIANG UNIVERSITY, Hangzhou (CN)
PCT Filed Jul. 8, 2019, PCT No. PCT/CN2019/095060
§ 371(c)(1), (2) Date Jul. 23, 2021,
PCT Pub. No. WO2020/151197, PCT Pub. Date Jul. 30, 2020.
Claims priority of application No. 201910073172.4 (CN), filed on Jan. 25, 2019.
Prior Publication US 2022/0096422 A1, Mar. 31, 2022
Int. Cl. A61K 31/337 (2006.01); A61K 31/352 (2006.01); A61K 31/713 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01)
CPC A61K 31/337 (2013.01) [A61K 31/352 (2013.01); A61K 31/713 (2013.01); A61K 47/64 (2017.08); A61P 35/00 (2018.01)] 17 Claims
OG exemplary drawing
 
1. A method for increasing blood-brain barrier permeability and enhancing the efficiency of transportation into the brain of a brain targeting drug delivery system, comprising administering to a subject an effective amount of SC79, and administering to the subject an effective amount of the brain targeting drug delivery system.